PTLA News and Press, Portola Pharmaceuticals Inc. From 05/08/19

Portola Pharmaceuticals ( PTLA ) Q1 results : Revenues: $22.2M (+236.4%); Collaboration and license revenue: $1.8M (-70.0%). More news on: Portola Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

Portola Pharmaceuticals (NASDAQ: PTLA ): Q1 Non-GAAP EPS of -$1.02 beats by $0.09 ; GAAP EPS of -$1.17 misses by $0.08 . More news on: Portola Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

– First Quarter Revenues of $22.2 Million;  Andexxa ® Product Revenues Grow 45% to $20.3 Million – – European Commission Approval of Ondexxya ® ; Staged Commercial Launch Planned in Second Half of 2019 – – Conf...

Portola Pharmaceuticals (NASDAQ: PTLA ) is scheduled to announce Q1 earnings results on Wednesday, May 8th, before market open. The consensus EPS Estimate is -$1.11 (+13.3% Y/Y) and the consensus Revenue Estimate is $20.6M (+212.1% Y/Y). Over the last 2 years, ptla has beaten EPS esti...

ACM , ANDX , ATHM , ATRO , BCOR , BG , BV , CBB , CBRE , CEIX , CFX , CHK , CORE , COTY , FOLD , FTDR , FUN , GCP , GOLD , GOLF , GTN , GTT , HMC , HZNP , ICPT , LXP , MCHP , MCK , MIDD , MPC , MPLX , MRNA , MSG , NXST , NYT , ODP , PFGC , PLUG , PTLA ...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Source: Shutterstock The stock market has continued to edge higher and the two major indexes, the Nasdaq ( QQQ ) and S&P 500 ( SPY ), touched the all-time high milestone last week. The steady gain reflects a diminishing concern relating to the pace of a global economic slowdown, as m...

Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...